샘플 요청 목록

 카트 문의
시장보고서
상품코드
2154090

차세대 시퀸서 시장

Next Generation Sequencers
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 636 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,834,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 14,886,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,504,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 시퀸서 시장은 2032년까지 361억 달러에 달할 전망

2025년에 109억 달러로 추계되는 세계의 차세대 시퀸서 시장은 2032년까지 361억 달러에 달할 것으로 예상되고 있으며, 2025-2032년까지의 분석 기간에 CAGR 18.6%로 성장할 것으로 전망되고 있습니다. 이 리포트에서 분석 대상이 되고 있는 부문의 하나인 플랫폼는 CAGR 20.4%를 기록하며, 분석 기간의 종료까지 241억 달러에 달할 것으로 예상되고 있습니다. 소모품 부문의 성장률은 분석 기간 중 CAGR 15.6%로 추정되고 있습니다.

미국 시장은 30억 달러로 추계되는 한편, 중국은 CAGR 24.3%로 성장할 것으로 예측됩니다.

미국의 차세대 시퀸서 시장은 2025년에 30억 달러로 추계되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025-2032년의 분석 기간에 CAGR 24.3%로 추이하며, 2032년까지 시장 규모가 84억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 CAGR 14.0% 및 17.2%로 성장할 것으로 예측됩니다. 유럽내에서는 독일이 CAGR 약 15.0%로 성장할 것으로 예측됩니다.

세계의 차세대 시퀸서 시장 - 주요 동향과 촉진요인의 개요

2005년에 시작된 차세대 염기서열 분석(NGS) 기술은 여러 DNA 가닥을 동시에 염기서열 분석할 수 있게 하여, 기존의 샌거(Sanger) 법에 비해 큰 진전을 이루며 유전학 분야에 혁명을 가져왔습니다. 당초 ‘초병렬 시퀀싱’이라 불렸던 이 기술은 전례 없는 속도와 비용 절감을 실현하여 대규모 게놈 연구를 더욱 친숙하게 만들었습니다. 상거 시퀀싱은 높은 정확도 덕분에 여전히 소규모 프로젝트나 NGS 결과의 검증에 활용되고 있지만, NGS는 효율성과 확장성이 뛰어나 한 번의 실행으로 다양한 샘플에 걸쳐 수백에서 수천 개의 유전자를 분석할 수 있습니다. NGS는 단일 염기 다형성부터 복잡한 구조 변이, RNA 융합에 이르기까지 광범위한 게놈 특성을 검출할 수 있으며, 지금까지 실현 불가능했던 광범위한 유전자 분석을 가능하게 하고 있습니다.

NGS는 처리량이 많을 뿐만 아니라, 필요한 시료량이 적고, 정확도가 높으며, 희귀한 유전적 변이를 검출할 수 있다는 점에서도 두드러집니다. 이러한 특성 덕분에 NGS는 의학, 농업, 환경 과학 등 다양한 분야에서 필수적인 툴이 되었으며, 게놈 연구, 임상 진단, 법의학 조사의 발전에 기여하고 있습니다. NGS의 과정은 복잡하며, 우선 시퀀싱 라이브러리 구축부터 시작됩니다. 이 공정에서는 DNA 또는 cDNA 샘플이 단편화되고, 식별을 용이하게 하기 위해 고유한 분자 어댑터에 결합됩니다. 이어서 ‘합성 기반 시퀀싱’ 접근법을 채택한 기술을 사용하여, 시퀀싱시 신호 감지 민감도를 높이기 위해 고체 표면에서 DNA 단편의 클론 증폭이 이루어집니다. 이 과정에 사용되는 장비는 광학 신호나, Ion Torrent 기술과 같이 DNA 합성 중에 방출되는 수소 이온에 의해 생성되는 전기 신호를 통해 각 뉴클레오티드의 첨가를 감지합니다. 데이터 분석 단계는 복잡하며, 원시 시퀀싱 데이터를 귀중한 유전학적 인사이트로 변환하기 위해 여러 해석 단계를 거쳐야 합니다.

다양한 분야에서 NGS가 폭넓게 응용되고 있는 것은 그 높은 처리량, 고속성, 그리고 비용 대비 효과라는 장점을 여실히 보여줍니다. 임상 연구에서 NGS는 질병과 관련된 유전적 변이를 규명하는 데 도움을 주어 표적 치료의 길을 열어주는 한편, 유전적 이상 선별을 통해 생식 의학 분야에서 매우 중요한 역할을 수행하고 있습니다. 농업 분야에서는 식물 유전학 연구를 촉진함으로써 작물 개량을 가속화하고, 더 강인한 작물 품종을 육성하는 데 기여하고 있습니다. NGS는 COVID-19 팬데믹과 같은 세계적 보건 위기 상황에서 바이러스의 게놈 시퀀싱을 신속하게 수행할 수 있게 하여, 변이 추적 및 백신 개발을 지원하는 데 있으며, 특히 중요한 역할을 해왔습니다. 클라우드 컴퓨팅과의 통합, 생물정보학의 발전, 맞춤형 의료에 대한 소비자의 관심 증가, 학술 및 임상 연구의 확대, 규제 및 윤리적 프레임워크의 진화, 전략적 제휴, 신흥 시장에 대한 투자 확대와 같은 성장 요인의 지원을 받아 지속적인 발전을 통해 맞춤형 의료 및 농업 개발 등을 한층 더 강화할 것으로 기대되며, NGS의 미래는 유망합니다.

부문:

제품·서비스(플랫폼 제품, 소모품), 기술(전게놈 시퀀싱(WGS) 기술, 전엑솜 시퀀싱 기술, 타겟 시퀀싱 및 리시퀀싱 기술, 기타 기술), 용도(종양학 용도, 임상 연구 용도, 생식 의료 용도, HLA 타이핑/면역계 모니터링 용도, 군유전체학/역학/Drug Discovery 용도, 농업유전체학 및 법의학 용도, 소비자 유전체학 도), 워크플로우(시퀀싱 전처리 워크플로우, 시퀀싱 워크플로우, NGS 데이터 해석 워크플로우), 최종 사용(학술연구 용, 임상 연구 용, 병원·진료소 용, 제약·바이오테크놀러지 기업용, 기타 최종 사용)

주요 기업

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Fluidigm Corporation
  • Illumina Inc.
  • Oxford Gene Technology
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California Inc.
  • QIAGEN N.V.
  • RainDance Technologies Inc.
  • Roche Sequencing
  • Thermo Fischer Scientific Inc.

각 분야의 전문가 관점을 바탕으로 합니다. - 산업계, 기업, 학계에 걸친 각 분야의 전문가들이 제시하는 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업의 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보원에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있으며, 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세히 검토합니다.

주요 지역의 시장 점유율을 면밀히 검토합니다. - 단일 글로벌 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구조는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞춰 상세도를 조정하여 주요 지역의 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA

Global Next Generation Sequencers Market to Reach US$36.1 Billion by 2032

The global market for Next Generation Sequencers estimated at US$10.9 Billion in the year 2025, is expected to reach US$36.1 Billion by 2032, growing at a CAGR of 18.6% over the analysis period 2025-2032. Platform Offering, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$24.1 Billion by the end of the analysis period. Growth in the Consumables Offering segment is estimated at 15.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 24.3% CAGR

The Next Generation Sequencers market in the U.S. is estimated at US$3.0 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2032 trailing a CAGR of 24.3% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.0% and 17.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Next Generation Sequencers Market - Key Trends and Drivers Summarized

Next-Generation Sequencing (NGS) technologies, initiated in 2005, have revolutionized the field of genetics by allowing for the simultaneous sequencing of multiple DNA strands, a significant advancement over the traditional Sanger sequencing. This technology, originally dubbed "massively-parallel sequencing," offers unprecedented speed and reduced costs, making extensive genomic studies more accessible. While Sanger sequencing is still utilized for smaller projects or to validate NGS results due to its high accuracy, NGS excels in efficiency and scalability, analyzing hundreds to thousands of genes across various samples in a single run. NGS detects a wide range of genomic features from single nucleotide variants to complex structural variations and RNA fusions, facilitating extensive genetic analyses that were previously unfeasible.

NGS stands out not just for its volume handling but also for its lower sample requirements, higher accuracy, and the ability to detect rare genetic variants. These attributes make it an essential tool in diverse fields such as medicine, agriculture, and environmental science, advancing genomic research, clinical diagnostics, and forensic investigations. The NGS process is intricate, beginning with the construction of a sequencing library where DNA or cDNA samples are fragmented and linked to unique molecular adaptors for easy identification. This is followed by clonal amplification of the DNA fragments on a solid surface to enhance signal detection during sequencing, using technologies that employ a 'sequencing by synthesis' approach. Instruments involved in this process detect each nucleotide addition either through optical signals or, as in Ion Torrent technology, electrical signals produced by hydrogen ions released during DNA synthesis. The data analysis phase is complex, involving multiple stages of interpretation to transform raw sequencing data into valuable genetic insights.

The broad application of NGS across various sectors underscores its advantages of high throughput, speed, and cost-efficiency. In clinical research, NGS aids in identifying genetic variations associated with diseases, paving the way for targeted therapies and playing a vital role in reproductive health through genetic anomaly screenings. In agriculture, it accelerates crop improvement by facilitating plant genetic studies, leading to the cultivation of more robust crop varieties. NGS has been particularly crucial during global health emergencies, such as the COVID-19 pandemic, by enabling rapid viral genomic sequencing, which assists in tracking mutations and vaccine development. The future of NGS looks promising with ongoing advancements expected to enhance personalized medicine, agricultural development, and more, fueled by growth drivers such as integration with cloud computing, advancements in bioinformatics, rising consumer interest in personalized medicine, expanding academic and clinical research, evolving regulatory and ethical frameworks, strategic collaborations, and increased investments in emerging markets.

SCOPE OF STUDY:

The report analyzes the Next Generation Sequencers market by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Platform Offering, Consumables Offering); Technology (WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology, Other Technologies); Application (Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application, Consumer Genomics Application); Workflow (Pre-Sequencing Workflow, Sequencing Workflow, NGS Data Analysis Workflow); End-Use (Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Fluidigm Corporation
  • Illumina Inc.
  • Oxford Gene Technology
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California Inc.
  • QIAGEN N.V.
  • RainDance Technologies Inc.
  • Roche Sequencing
  • Thermo Fischer Scientific Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global EconomicUpdate
    • Next Generation Sequencers - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 93 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Sequencing Technologies Expand Addressable Market Opportunity
    • Increased Adoption in Clinical Diagnostics Throws the Spotlight on Sequencing Applications
    • Rising Demand for Personalized Medicine Drives Adoption of NGS
    • Integration with Artificial Intelligence and Big Data Analytics Generates New Opportunities
    • Technological Innovations in Sample Preparation and Library Construction Spur Growth
    • Growing Utilization in Oncology Research Expands Market Potential
    • Emergence of Single-Cell Sequencing Drives Adoption of Advanced NGS Technologies
    • Focus on Rare Disease Diagnostics Generates Demand for High-Throughput Sequencing
    • Development of Portable and Real-Time Sequencing Devices Expands Addressable Market
    • Rising Investments in Genomic Research Strengthens Market Demand
    • Adoption of NGS in Infectious Disease Surveillance Generates New Opportunities
    • Consumer Demand for Ancestry and Genetic Testing Drives Market Adoption
    • Integration with CRISPR and Gene Editing Technologies Generates Demand for NGS
    • Focus on Precision Medicine and Targeted Therapies Strengthens Business Case for NGS
    • Emerging Applications in Microbiome Research Propel Growth in NGS Utilization
    • Challenges in Regulatory Compliance and Quality Control
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 4: World Next Generation Sequencers Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Next Generation Sequencers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Next Generation Sequencers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Next Generation Sequencers by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Platform Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Platform Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Platform Offering by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Consumables Offering by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for WGS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for WGS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for WGS Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Whole Exome Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Whole Exome Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Whole Exome Sequencing Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Targeted Sequencing & Resequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Targeted Sequencing & Resequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Targeted Sequencing & Resequencing Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Clinical Investigation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Clinical Investigation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Clinical Investigation Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Reproductive Health Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for HLA Typing / Immune System Monitoring Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for HLA Typing / Immune System Monitoring Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for HLA Typing / Immune System Monitoring Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Metagenomics / Epidemiology / Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Metagenomics / Epidemiology / Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Metagenomics / Epidemiology / Drug Development Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Agrigenomics & Forensics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Agrigenomics & Forensics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Agrigenomics & Forensics Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Consumer Genomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Consumer Genomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Consumer Genomics Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 47: World Recent Past, Current & Future Analysis for Pre-Sequencing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 48: World Historic Review for Pre-Sequencing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: World 13-Year Perspective for Pre-Sequencing Workflow by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 50: World Recent Past, Current & Future Analysis for Sequencing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 51: World Historic Review for Sequencing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: World 13-Year Perspective for Sequencing Workflow by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 53: World Recent Past, Current & Future Analysis for NGS Data Analysis Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 54: World Historic Review for NGS Data Analysis Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: World 13-Year Perspective for NGS Data Analysis Workflow by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 56: World Recent Past, Current & Future Analysis for Academic Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 57: World Historic Review for Academic Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: World 13-Year Perspective for Academic Research End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 59: World Recent Past, Current & Future Analysis for Clinical Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 60: World Historic Review for Clinical Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: World 13-Year Perspective for Clinical Research End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 62: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 63: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: World 13-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 65: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 66: World Historic Review for Pharma & Biotech Entities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: World 13-Year Perspective for Pharma & Biotech Entities End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 68: USA Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: USA Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: USA 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 71: USA Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: USA Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: USA 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 74: USA Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: USA Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: USA 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 77: USA Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: USA Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: USA 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 80: USA Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: USA Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: USA 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Canada Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Canada 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Canada Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Canada 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 89: Canada Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Canada Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Canada 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 92: Canada Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Canada Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Canada 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 95: Canada Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Canada Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Canada 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • JAPAN
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Japan Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Japan 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 101: Japan Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Japan Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Japan 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 104: Japan Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Japan Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Japan 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 107: Japan Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Japan Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Japan 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 110: Japan Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Japan Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Japan 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • CHINA
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 113: China Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: China Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: China 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 116: China Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: China Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: China 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 119: China Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: China Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: China 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 122: China Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: China Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: China 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 125: China Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: China Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: China 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • EUROPE
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Europe Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Europe 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 131: Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 132: Europe Historic Review for Next Generation Sequencers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Europe 13-Year Perspective for Next Generation Sequencers by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 134: Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Europe Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Europe 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 137: Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Europe Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Europe 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 140: Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Europe Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Europe 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 143: Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Europe Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Europe 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • FRANCE
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 146: France Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: France Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: France 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 149: France Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: France Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: France 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 152: France Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: France Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: France 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 155: France Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: France Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: France 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 158: France Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: France Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: France 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • GERMANY
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 161: Germany Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Germany Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Germany 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 164: Germany Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Germany Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Germany 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 167: Germany Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Germany Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Germany 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 170: Germany Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Germany Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Germany 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 173: Germany Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Germany Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Germany 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 176: Italy Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Italy Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Italy 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 179: Italy Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Italy Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Italy 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 182: Italy Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Italy Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Italy 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 185: Italy Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Italy Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Italy 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 188: Italy Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Italy Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Italy 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 191: UK Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: UK Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: UK 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 194: UK Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: UK Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: UK 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 197: UK Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: UK Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: UK 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 200: UK Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: UK Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: UK 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 203: UK Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: UK Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: UK 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 206: Spain Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Spain Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Spain 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 209: Spain Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Spain Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Spain 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 212: Spain Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Spain Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Spain 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 215: Spain Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Spain Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Spain 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 218: Spain Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Spain Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Spain 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 221: Russia Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Russia Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Russia 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 224: Russia Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Russia Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Russia 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 227: Russia Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Russia Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Russia 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 230: Russia Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Russia Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Russia 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 233: Russia Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Russia Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Russia 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Europe Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Europe 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Europe Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Europe 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Europe Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Europe 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 245: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Europe Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Europe 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 248: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Europe Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Europe 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Next Generation Sequencers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Asia-Pacific Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Asia-Pacific Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Asia-Pacific Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 263: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Asia-Pacific Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
    • TABLE 266: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Asia-Pacific Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Asia-Pacific 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 269: Australia Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Australia Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Australia 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 272: Australia Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Australia Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Australia 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 275: Australia Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Australia Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Australia 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 278: Australia Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Australia Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Australia 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
    • TABLE 281: Australia Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Australia Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Australia 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • INDIA
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 284: India Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: India Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: India 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 287: India Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: India Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: India 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 290: India Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: India Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: India 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 293: India Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: India Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: India 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
    • TABLE 296: India Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: India Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: India 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 299: South Korea Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: South Korea Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: South Korea 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 302: South Korea Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: South Korea Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: South Korea 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 305: South Korea Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: South Korea Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: South Korea 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 308: South Korea Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: South Korea Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: South Korea 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
    • TABLE 311: South Korea Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: South Korea Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: South Korea 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Asia-Pacific Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Asia-Pacific Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Rest of Asia-Pacific Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Rest of Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 323: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Rest of Asia-Pacific Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Rest of Asia-Pacific 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
    • TABLE 326: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Rest of Asia-Pacific Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Rest of Asia-Pacific 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 330: Latin America Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 331: Latin America 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 332: Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 333: Latin America Historic Review for Next Generation Sequencers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 334: Latin America 13-Year Perspective for Next Generation Sequencers by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 335: Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Latin America Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 337: Latin America 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 338: Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Latin America Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 340: Latin America 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 341: Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Latin America Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 343: Latin America 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 344: Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Latin America Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 346: Latin America 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 347: Argentina Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Argentina Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 349: Argentina 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 350: Argentina Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Argentina Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 352: Argentina 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 353: Argentina Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Argentina Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 355: Argentina 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 356: Argentina Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Argentina Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 358: Argentina 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 359: Argentina Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Argentina Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 361: Argentina 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 362: Brazil Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Brazil Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 364: Brazil 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 365: Brazil Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Brazil Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 367: Brazil 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 368: Brazil Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 369: Brazil Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 370: Brazil 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 371: Brazil Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 372: Brazil Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 373: Brazil 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 374: Brazil Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 375: Brazil Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 376: Brazil 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 377: Mexico Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 378: Mexico Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 379: Mexico 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 380: Mexico Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 381: Mexico Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 382: Mexico 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 383: Mexico Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 384: Mexico Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 385: Mexico 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 386: Mexico Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 387: Mexico Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 388: Mexico 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 389: Mexico Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Mexico Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 391: Mexico 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Rest of Latin America Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 394: Rest of Latin America 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Rest of Latin America Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 397: Rest of Latin America 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Rest of Latin America Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 400: Rest of Latin America 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 401: Rest of Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 402: Rest of Latin America Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 403: Rest of Latin America 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 404: Rest of Latin America Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 405: Rest of Latin America Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 406: Rest of Latin America 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 408: Middle East Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 409: Middle East 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 410: Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 411: Middle East Historic Review for Next Generation Sequencers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 412: Middle East 13-Year Perspective for Next Generation Sequencers by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 413: Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 414: Middle East Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 415: Middle East 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 416: Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 417: Middle East Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 418: Middle East 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 419: Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 420: Middle East Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 421: Middle East 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 422: Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 423: Middle East Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 424: Middle East 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 425: Iran Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 426: Iran Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 427: Iran 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 428: Iran Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 429: Iran Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 430: Iran 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 431: Iran Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 432: Iran Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 433: Iran 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 434: Iran Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 435: Iran Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 436: Iran 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 437: Iran Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 438: Iran Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 439: Iran 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 440: Israel Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 441: Israel Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 442: Israel 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 443: Israel Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 444: Israel Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 445: Israel 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 446: Israel Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 447: Israel Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 448: Israel 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 449: Israel Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 450: Israel Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 451: Israel 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 452: Israel Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 453: Israel Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 454: Israel 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 456: Saudi Arabia Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 457: Saudi Arabia 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 459: Saudi Arabia Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 460: Saudi Arabia 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 462: Saudi Arabia Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 463: Saudi Arabia 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 464: Saudi Arabia Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 465: Saudi Arabia Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 466: Saudi Arabia 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 467: Saudi Arabia Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 468: Saudi Arabia Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 469: Saudi Arabia 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 470: UAE Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 471: UAE Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 472: UAE 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 473: UAE Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 474: UAE Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 475: UAE 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 476: UAE Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 477: UAE Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 478: UAE 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 479: UAE Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 480: UAE Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 481: UAE 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 482: UAE Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 483: UAE Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 484: UAE 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 486: Rest of Middle East Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 487: Rest of Middle East 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 489: Rest of Middle East Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 490: Rest of Middle East 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 492: Rest of Middle East Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 493: Rest of Middle East 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 494: Rest of Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 495: Rest of Middle East Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 496: Rest of Middle East 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 497: Rest of Middle East Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 498: Rest of Middle East Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 499: Rest of Middle East 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032
  • AFRICA
    • Next Generation Sequencers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 500: Africa Recent Past, Current & Future Analysis for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 501: Africa Historic Review for Next Generation Sequencers by End-Use - Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 502: Africa 13-Year Perspective for Next Generation Sequencers by End-Use - Percentage Breakdown of Value Revenues for Academic Research End-Use, Clinical Research End-Use, Hospitals & Clinics End-Use, Pharma & Biotech Entities End-Use and Other End-Uses for the Years 2020, 2026 & 2032
    • TABLE 503: Africa Recent Past, Current & Future Analysis for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 504: Africa Historic Review for Next Generation Sequencers by Offering - Platform Offering and Consumables Offering Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 505: Africa 13-Year Perspective for Next Generation Sequencers by Offering - Percentage Breakdown of Value Revenues for Platform Offering and Consumables Offering for the Years 2020, 2026 & 2032
    • TABLE 506: Africa Recent Past, Current & Future Analysis for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 507: Africa Historic Review for Next Generation Sequencers by Technology - WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 508: Africa 13-Year Perspective for Next Generation Sequencers by Technology - Percentage Breakdown of Value Revenues for WGS Technology, Whole Exome Sequencing Technology, Targeted Sequencing & Resequencing Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 509: Africa Recent Past, Current & Future Analysis for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 510: Africa Historic Review for Next Generation Sequencers by Application - Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 511: Africa 13-Year Perspective for Next Generation Sequencers by Application - Percentage Breakdown of Value Revenues for Oncology Application, Clinical Investigation Application, Reproductive Health Application, HLA Typing / Immune System Monitoring Application, Metagenomics / Epidemiology / Drug Development Application, Agrigenomics & Forensics Application and Consumer Genomics Application for the Years 2020, 2026 & 2032
    • TABLE 512: Africa Recent Past, Current & Future Analysis for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow - Independent Analysis of Annual Revenues in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 513: Africa Historic Review for Next Generation Sequencers by Workflow - Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 514: Africa 13-Year Perspective for Next Generation Sequencers by Workflow - Percentage Breakdown of Value Revenues for Pre-Sequencing Workflow, Sequencing Workflow and NGS Data Analysis Workflow for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기